Killer T Cells surround a cancer cell Source: NIH

In the race for BCMA CAR-T dominance, we’ve long accepted a grim trade-off – to get industry leading response rates, you have to accept the risk of delayed movement and neurocognitive toxicities (MNTs).

Recent data from several groups are finally converging on why some constructs trigger these delayed events while others don’t.

The findings suggest the early belief that these issues were a result of higher expansion was likely off the mark…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers